Analyst Jason Butler of JMP Securities reiterated a Buy rating on Esperion (ESPR – Research Report), retaining the price target of $4.00.
Jason Butler has given his Buy rating due to a combination of factors that highlight potential growth and value for Esperion. The company is advancing its Phase 3 development of bempedoic acid for pediatric patients with familial hypercholesterolemia, which could lead to label expansion opportunities. This expansion is expected to provide an additional six months of patent protection, potentially adding significant value to the company’s net present value.
Moreover, the ongoing trials and planned Phase 3 studies in pediatric patients demonstrate Esperion’s commitment to addressing unmet medical needs, which could enhance the franchise’s market position. Even without immediate sales increases from these expansions, the extension of brand exclusivity alone is projected to contribute approximately $200 million to Esperion’s valuation. These strategic moves underscore the company’s potential for growth, supporting the Buy rating.
In another report released on March 20, H.C. Wainwright also maintained a Buy rating on the stock with a $16.00 price target.